N/A N=132 Anticoagulation Therapy in the Very Old
Atrial Fibrillation
Primary: Number of Patients Experiencing Stroke — 2; 2; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Venous Thromboembolism
Primary: Time Spent Per PT/INR Monitoring Encounter — 19.4; 47 minutes
N/A N=1,260,576 Improving Anticoagulation Control in VISN 1
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
Phase 2 N=14 Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
N/A N=26 Strategies for Anticoagulation During Venovenous ECMO
Acute Hypoxemic Respiratory Failure · Anticoagulant-induced Bleeding · Thromboembolism
Primary: Number of Participants With Major Bleeding Events — 1; 4 Participants
N/A N=73,989 Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
Non-valvular Atrial Fibrillation
Primary: Event Rate Per 100 Participant-Years For First Occurrence of Stroke and Systemic Embolism Events After Index Date — 3.2; 1.67; 2.08; 1.79 Events Per 100…
Phase 4 N=1,829 How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
Acute ST Elevation Myocardial Infarction
Primary: Major Adverse Cardiac Events (MACE) in Terms of the Incidence of All Cause Mortality, Cerebrovascular Accident, Re-infarction and Additional Unplanned Target Lesion…
Phase 2 N=20 Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
Heparin-induced Thrombocytopenia Type II
Primary: Composite of All-cause Death, Thrombosis (New and Extended) and Unplanned Amputation — 10 participants
N/A N=10 Blood Loss at the Time of First Trimester Surgical Abortion in Anticoagulated Women
Blood Loss
Primary: Volume of Intraoperative Blood Loss — 91.5; 52.2 milliliters
N/A N=35 Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Coronary Artery Disease
Primary: TRAP-induced Platelet Aggregation — 74; 77 percentage of aggregation — p=<0.05
Phase 2 N=200 Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass
Acquired Antithrombin III Deficiency · Coronary Artery Bypass
Primary: Postoperative ATIII Levels at the ICU Admission — 94.06; 64.70 IU — p=<0.0001
N/A N=341 Anticoagulation With Enhanced Gastrointestinal Safety
Upper Gastrointestinal Bleeding · Peptic Ulcer Hemorrhage · Anticoagulant-induced Bleeding
Primary: ITT Analysis - Percent of Patients Reporting Medication Optimization — 30; 2; 29; 65 Participants — p=<0.001
Phase 2 N=40 Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
ATIII Deficiency
Primary: Difference in the Mean and Standard Deviation (SD) of the Calibrated Automated Thrombography (CAT) Measurements of the Control and ATIII Groups at Time 5 (on Arrival in…
Phase 2 N=44 Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Inflammation · Coagulation · HIV Infection
Primary: Change in Interleukin 6 (IL-6) Plasma Levels From Baseline to 4 Months. — -0.02; 0.09 ln-pg/mL — p=0.26
Phase 4 N=64 Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis
Liver Cirrhosis · Portal Vein Thrombosis
Primary: Recanalization Rate — 20; 11 Participants
Phase 3 N=465 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
Phase 4 N=516 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis
Thrombosis
Primary: Major Bleeding — 0 participants
N/A N=333,664 Anticoagulant Utilization Pattern
Atrial Fibrillation
Primary: Description of the Characteristics of Anticoagulant Initiators — 3.41; 4.30; 3.59; 3.82 Scores on a scale
N/A N=63 Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
Upper Gastrointestinal Bleeding
Primary: The Proportion of Randomized Patients That Complete a Brief Medication Review Phone Call at Week 5 — 7; 12; 8; 8 Participants
N/A N=148 PRescriptiOn PattERns Of Oral Anticoagulants
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
N/A N=300 Simplified Anti-Thrombotic Therapy for FFR
Coronary Artery Disease
Primary: Thrombotic Complications — 0; 0; 0 Number of Patients — p=1
Phase 4 N=66 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque
Atrial Fibrillation
Primary: Coronary Artery Calcium (CAC) Score — 66; 31 units on a scale
Phase 2 N=55 Antiplatelet Therapy in HIV
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
N/A N=20 Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
Left Sided Heart Failure · Left Ventricular Assist Device · Anticoagulant Therapy
Primary: Nomogram Feasibility — 136; 112; 136; 111 Surveys — p=.45
Phase 4 N=81 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Coronary Artery Disease
Primary: Platelet Reactivity Measured as PRU — 154.5; 23; 104 PRU
Phase 4 N=101 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Dementia · Cognition Disorders · Cerebral Ischemic Events
Primary: Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist — 0; 0 Participants
N/A N=100 Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation
Bradycardia · Tachycardia · Atrial Fibrillation
Primary: Bleeding Complication — 0; 2; 0; 2 participants
N/A N=70 Transcranial Doppler (TCD) Assessment During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement
Aortic Valve Disease
Primary: Differences in the Rate of Doppler-detected Cerebral Micro Emboli Between the Two Prophylactic Treatments of Thrombosis — 1.1; 0.7; 1.0; 0.7 MES counts
Phase 3 N=1,506 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Atrial Fibrillation
Primary: Number of Participants With Adjudicated Major or Clinically Relevant Non-major Bleeding As First Event Defined by International Society on Thrombosis and Haemostasis…
Phase 3 N=1,884 Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
Arterial Thromboembolic Events · Atrial Fibrillation
Primary: Number of Arterial Thromboembolic Events — 2; 3; 2; 0 Arterial thromboembolic events